Silencing Disease: Shifting Treatment Paradigms with RNAi Therapeutics ft. Alnylam’s Dr. Kirk Brown 

In this episode, Ayesha spoke with Kirk Brown, PhD, Vice President of Research at Alnylam Pharmaceuticals.
Alnylam is focused on developing RNAi medicines to transform the way diseases like cardiovascular and neurological diseases are treated.
Dr. Brown’s preclinical work combining stable siRNA designs with alternative conjugation strategies has enabled potent, long-lasting silencing across the CNS following a single intrathecal administration.
In addition to driving RNAi platform innovations, Dr. Brown leads a team of CNS target biologists at Alnylam and serves as the research lead for ALN-APP, the first clinical CNS RNAi program.
In this episode, Dr. Brown discusses the promise and evolving landscape of RNAi therapeutics across various therapeutic areas and Alnylam’s approach to developing innovative RNAi medicines.
For more life science and medical device content, visit the Xtalks Vitals homepage. xtalks.com/vit...
Follow Us on Social Media
Twitter: / xtalks
Instagram: / xtalks
Facebook: / xtalks.webinars
LinkedIn: / xtalks-webconferences
RU-vid: / xtalkswebinars